

United States Patent [19]

Golub et al.

[11] Patent Number: 4,666,897

[45] Date of Patent: May 19, 1987

[54] INHIBITION OF MAMMALIAN COLLAGENOLYTIC ENZYMES BY TETRACYCLINES

[75] Inventors: Lorne M. Golub, Smithtown; Thomas F. McNamara, Port Jefferson; N. S. Ramamurthy, Smithtown, all of N.Y.

[73] Assignee: Research Foundation of State University, Albany, N.Y.

[21] Appl. No.: 566,517

[22] Filed: Dec. 29, 1983

[51] Int. Cl. 4 A61K 31/65

[52] U.S. Cl. 514/152

[58] Field of Search 424/227; 514/152

[56] References Cited

U.S. PATENT DOCUMENTS

2,895,880	7/1959	Rosenthal	424/227
4,248,892	2/1981	Kanamaru et al.	424/317
4,371,465	2/1983	McGregor	424/177
4,457,936	7/1984	Draeger et al.	424/270

OTHER PUBLICATIONS

- Bauer, et al., 1983, J. Invest. Dermatol., vol. 81, pp. 162, 163 168.
Harris, et al., 1984, Collagen Rel. Res., vol. 4, p. 493.
Berman and Manabe, 1973, Ann. Ophthalmol., Nov., p. 1193.
Golub, et al., 1985, J. Periodontal Res., vol. 20, pp. 12-23.
Welgus and Stricklin, 1983, J. Biol. Chem., vol. 258, p. 12259.
Uitto, et al., 1984, J. Oral. Path., vol. 13, p. 412.

Narayanan and Page., 1983, Collagen Rel. Res., vol. 3, p. 54.

Golub, et al., 1985, J. Periodontal. Res., Special Issue, p. 93.

Vater, et al., 1978, J. Clin. Invest., vol. 62, p. 987.

Harris, et al., 1984, Collagen Rel. Res., vol. 4, pp. 504-505.

Cowen, et al., 1985, Biochem. International, vol. 11, p. 273.

Belaisse, et al., 1985, Biochem. Biophys. Res. Commun., vol. 133, p. 483.

Golub, et al., 1983, J. Periodontal Res., vol. 18, pp. 516-526.

Chemical Abstracts 100:96203a (1983).

Chemical Abstracts, 93:142977t (1980).

Chemical Abstracts, 76:30596k (1969).

Dreisbach et al., Induction of Collagenase Production in Vibrio B-30, J. Bacterial, vol. 135, No. 2 (1978) pp. 521-527.

Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th ed., pp. 961-962 (1980).

Primary Examiner—Albert T. Meyers

Assistant Examiner—John M. Kilcoyne

Attorney, Agent, or Firm—Omri M. Behr

[57] ABSTRACT

A method of reducing pathologically excessive levels of activity of collagenolytic enzymes in mammals to substantially normal levels by administering 10-100% of the normal antibiotic therapeutic dose of a tetracycline is disclosed.

10 Claims, 8 Drawing Figures